Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of May 2022, with the report dated May 13, 2022. The filing discloses material corporate governance changes involving the resignation of two independent directors and the subsequent appointment of two new independent directors to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material changes reported are:
- Resignations: On May 9, 2022, Mr. Junsong Li and Mr. Wenwei Fan resigned from their positions as independent directors and all associated committee roles (Compensation, Audit, Nominating and Corporate Governance) effective immediately. The resignations were for personal reasons and not due to disagreements with the Company.
- Appointments: On May 10, 2022, the Board appointed Mr. Tong Liu and Mr. Songfan He as independent directors to fill the vacancies. Mr. Liu assumed the role of Chairman of the Compensation Committee, while Mr. He assumed the role of Chairman of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are discussed beyond the standard disclosure that the resignations were not related to operational disagreements. The filing notes that the new directors will receive an annual director fee of $1 in cash, payable quarterly, plus reimbursement for reasonable expenses.
Key Facts for Investor Verification
- Verify the qualifications and potential conflicts of interest for the newly appointed directors, Mr. Tong Liu (legal background) and Mr. Songfan He (medical background).
- Confirm the composition of the Audit and Compensation Committees following the leadership changes.
- Note the nominal director fee structure ($1 annually) for the new appointees.
- Review the attached offer letters (Exhibits 10.1 and 10.2) for complete terms of employment.